By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French gene expression-based diagnostics developer TcLand Expression today announced it has received €1.2 million ($1.7 million) to perform a validation study of a test for rheumatoid arthritis.

The funding from Oseo and the European Regional Development Fund will be used primarily to set up a European multi-center clinical trial for the validation of a molecular test to predict non-response to anti-TNF treatment, in particular Remicade (infliximab).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.